A Study of APG-3288 in Relapsed/Refractory Blood Cancers

计划入组 180 人 · 首次发布于 2026 年 2 月 20 日

Clinical Trial of AVL-3288 in Schizophrenia Patients

计划入组 24 人 · 首次发布于 2016 年 12 月 1 日

The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine

首次发布于 2017 年 9 月 13 日

AVL-3288

APG-2449

APG-2305

Richen Europe S.r.l.

Italy

INCOME AMG RTS25OCTD

PPG Industries

United States

Ascentage Pharma Receives FDA Clearance for Novel BTK Protein Degrader APG-3288 in B-Cell Malignancies

Ascentage Pharma's APG-2449 Advances to Phase III Trials for NSCLC Treatment

Natera and Aveta Biomics Partner on Global Phase 3 Trial of Oral Immunotherapy APG-157 in Head and Neck Cancer